scholarly journals Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes

Core Evidence ◽  
2011 ◽  
pp. 67 ◽  
Author(s):  
Anthony Barnett
Keyword(s):  
Type 2 Diabetes ◽  
Potential Use

scholarly journals Farnesoid X Receptor an Emerging Target to Combat Obesity

2017 ◽  
Vol 35 (3) ◽  
pp. 185-190 ◽  
Author(s):  
C. Daniel De Magalhaes Filho ◽  
Michael Downes ◽  
Ronald M. Evans
Keyword(s):  
Type 2 Diabetes ◽  
Bile Acid ◽  
Treatment Options ◽  
Farnesoid X Receptor ◽  
Whole Body ◽  
Body Lipid ◽  
Associated Diseases ◽  
Attractive Candidate ◽  
Potential Use

Obesity and its associated diseases, including type 2 diabetes, have reached epidemic levels worldwide. However, available treatment options are limited and ineffective in managing the disease. There is therefore an urgent need for the development of new pharmacological solutions. The bile acid (BA) Farnesoid X receptor (FXR) has recently emerged as an attractive candidate. Initially described for their role in lipid and vitamin absorption from diet, BAs are hormones with powerful effects on whole body lipid and glucose metabolism. In this review, we focus on FXR and how 2 decades of work on this receptor, both in rodents and humans, have led to the development of drug agonists with potential use in humans for treatment of conditions ranging from obesity-associated diseases to BA dysregulation.

The potential use of biomarkers in the prevention of Type 2 diabetes

2013 ◽  
Vol 8 (3) ◽  
pp. 217-219 ◽  
Author(s):  
Astrid Steinbrecher ◽  
Tobias Pischon
Keyword(s):  
Type 2 Diabetes ◽  
Potential Use

scholarly journals Chemical Composition andα-Glucosidase Inhibitory Activity of VietnameseCitrusPeels Essential Oils

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Nguyen Hai Dang ◽  
Pham Huong Nhung ◽  
Bui Thi Mai Anh ◽  
Dinh Thi Thu Thuy ◽  
Chau Van Minh ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Chemical Composition ◽  
Essential Oil ◽  
Essential Oils ◽  
Inhibitory Activity ◽  
Inhibitory Effect ◽  
Potential Use

Background. Inhibition ofα-glucosidase is an important factor to control postprandial hyperglycemia in type 2 diabetes mellitus.Citrusessential oils (CEO) are among the most widely used essential oils, and some of them exhibited promising antidiabetic effect. However, theα-glucosidase inhibition of CEO has not been investigated so far. The present work aims to evaluate theα-glucosidase inhibition of essential oils from six VietnameseCitruspeels.Methods. The chemical composition of essential oils obtained by hydrodistillation from sixCitruspeels was analyzed by GC-MS. All essential oils were tested for their inhibitory activity onα-glucosidase usingp-nitrophenyl-α-D-glucopyranoside as substrate.Results. In Buddha’s hand and lime peels, the major components were limonene (59.0–61.31%) andγ-terpinene (13.98–23.84%) while limonene (90.95–95.74%) was most abundant in pomelo, orange, tangerine, and calamondin peels. Among the essential oils, the Buddha’s hand oil showed the most significantα-glucosidase inhibitory effect with the IC50value of 412.2 μg/mL. The combination of the Buddha’s hand essential oil and the antidiabetic drug acarbose increased the inhibitory effect.Conclusions. The results suggested the potential use of Buddha’s hand essential oil as an alternative in treatment of type 2 diabetes mellitus.

scholarly journals Glucose-Sensing Transcription Factor MondoA/ChREBP as Targets for Type 2 Diabetes: Opportunities and Challenges

2019 ◽  
Vol 20 (20) ◽  
pp. 5132 ◽  
Author(s):  
Ziyi Song ◽  
Hao Yang ◽  
Lei Zhou ◽  
Fajun Yang
Keyword(s):  
Type 2 Diabetes ◽  
Drug Targets ◽  
Metabolic Disorders ◽  
Glucose Sensing ◽  
Health Concern ◽  
Major Health ◽  
Pathological Conditions ◽  
Element Binding Protein ◽  
Potential Use

The worldwide increase in type 2 diabetes (T2D) is becoming a major health concern, thus searching for novel preventive and therapeutic strategies has become urgent. In last decade, the paralogous transcription factors MondoA and carbohydrate response element-binding protein (ChREBP) have been revealed to be central mediators of glucose sensing in multiple metabolic organs. Under normal nutrient conditions, MondoA/ChREBP plays vital roles in maintaining glucose homeostasis. However, under chronic nutrient overload, the dysregulation of MondoA/ChREBP contributes to metabolic disorders, such as insulin resistance (IR) and T2D. In this review, we aim to provide an overview of recent advances in the understanding of MondoA/ChREBP and its roles in T2D development. Specifically, we will briefly summarize the functional similarities and differences between MondoA and ChREBP. Then, we will update the roles of MondoA/ChREBP in four T2D-associated metabolic organs (i.e., the skeletal muscle, liver, adipose tissue, and pancreas) in physiological and pathological conditions. Finally, we will discuss the opportunities and challenges of MondoA/ChREBP as drug targets for anti-diabetes. By doing so, we highlight the potential use of therapies targeting MondoA/ChREBP to counteract T2D and its complications.

Expression study of candidate miRNAs and evaluation of their potential use as biomarkers of diabetic neuropathy

Epigenomics ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 575-585 ◽  
Author(s):  
Cinzia Ciccacci ◽  
Andrea Latini ◽  
Antonella Colantuono ◽  
Cristina Politi ◽  
Cinzia D'Amato ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Diabetic Neuropathy ◽  
Diabetic Polyneuropathy ◽  
Wild Type Allele ◽  
Wild Type ◽  
Expression Study ◽  
Candidate Mirnas ◽  
Potential Use ◽  
Lower Expression

Aim: To evaluate the expression of candidate miRNAs in relation to diabetic polyneuropathy (DPN) and cardiovascular autonomic neuropathy (CAN). Materials & methods: The expression of six candidate miRNAs has been evaluated in 49 Type 2 diabetes patients with neurological evaluation. Results: A higher expression of miR-128a was seen in patients with DPN compared with those without DPN (p = 0.015). miR-155 and miR-499a seemed to be down-expressed in patients with DPN (p = 0.04 and p = 0.05, respectively). A lower expression of miR-155 (p = 0.05) was observed even in patients with CAN with respect to CAN-negative. A higher expression of miR-155 was associated with the rs767649 polymorphism variant allele compared with the wild-type allele (p = 0.03). Conclusion: miR-128a, miR-155 and miR-499a might be involved in diabetic neuropathies development.

Sign in / Sign up

Export Citation Format

Share Document